{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:51:55Z","timestamp":1785448315759,"version":"3.56.0"},"reference-count":20,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T00:00:00Z","timestamp":1545004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C7627\/A9080"],"award-info":[{"award-number":["C7627\/A9080"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Mantle cell lymphoma (<jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>) is an aggressive form of non\u2010Hodgkin lymphoma that remains incurable for the majority of patients. Allogeneic stem cell transplantation (allo<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content>) produces long\u2010term disease\u2010free remissions for around 30\u201340% patients, however it is reserved for the treatment of relapsed disease. This study examined the use of front line transplantation for young patients in an attempt to improve outcomes. Twenty\u2010five patients received an allo<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> using <jats:styled-content style=\"fixed-case\">BEAM<\/jats:styled-content> [<jats:styled-content style=\"fixed-case\">BCNU<\/jats:styled-content> (carmustine), etoposide, cytarabine, melphalan)\u2010Campath conditioning following permissive induction therapy from both related and unrelated donors. This was a multi\u2010centre prospective trial. Twenty\u2010four of 25 patients engrafted with no non\u2010relapse mortality events by day 100. With a median follow\u2010up of 60\u00b75\u00a0months, there have been six deaths (3 from <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>). The progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) and overall survival were 68% and 80% at 2\u00a0years and 56% and 76% at 5\u00a0years. <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> was very similar for both sibling and unrelated transplants and there was no difference in <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> between patients with respect to remission status prior to transplantation. Nine (38%) patients experienced acute graft\u2010versus\u2010host disease (<jats:styled-content style=\"fixed-case\">GVHD<\/jats:styled-content>) and 14 (58%) experienced chronic <jats:styled-content style=\"fixed-case\">GVHD<\/jats:styled-content>, of which 8 were extensive. Front line allo<jats:styled-content style=\"fixed-case\">SCT<\/jats:styled-content> is feasible but should only be considered for patients at high risk of early progression following conventional therapy.<\/jats:p>","DOI":"10.1111\/bjh.15723","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T01:05:08Z","timestamp":1545095108000},"page":"999-1005","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma"],"prefix":"10.1111","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8937-6351","authenticated-orcid":false,"given":"Simon","family":"Rule","sequence":"first","affiliation":[{"name":"Plymouth University Medical School Plymouth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[{"name":"Leeds Institute of Cancer &amp; Pathology University of Leeds Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel H.","family":"Russell","sequence":"additional","affiliation":[{"name":"Nottingham University Hospital Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Hunter","sequence":"additional","affiliation":[{"name":"Department of Haematology Leicester Royal Infirmary Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Haematology University Hospitals Bristol Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Morley","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospital NHS Foundation Trust Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"Haematology Department Addenbrookes Hospital Cambridge University Hospitals Cambridge UK"},{"name":"Clinical Hematology Department Catalan Institute of Oncology Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pip","family":"Patrick","sequence":"additional","affiliation":[{"name":"Cancer Research UK and University College London Cancer Trials Centre  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Clifton\u2010Hadley","sequence":"additional","affiliation":[{"name":"Cancer Research UK and University College London Cancer Trials Centre  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyin","family":"Adedayo","sequence":"additional","affiliation":[{"name":"Cancer Research UK and University College London Cancer Trials Centre  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Kirkwood","sequence":"additional","affiliation":[{"name":"Cancer Research UK and University College London Cancer Trials Centre  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl S.","family":"Peggs","sequence":"additional","affiliation":[{"name":"Department of Haematology University College London Cancer Institute London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,12,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-521898"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.04.006"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu264"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14241"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779736"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2454"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09174.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.501"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2087-z"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds054"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"},{"key":"e_1_2_8_14_1","first-page":"3535","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2\u00a0Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris M.B.","year":"2004","journal-title":"Cell"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15283"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.223"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0067-3"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08228.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29498"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15723","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15723","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T16:30:25Z","timestamp":1694709025000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,17]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1111\/bjh.15723"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15723","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,17]]},"assertion":[{"value":"2018-08-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}